These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 20089137)

  • 1. Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.
    Perez-Costas E; Melendez-Ferro M; Roberts RC
    J Neurochem; 2010 Apr; 113(2):287-302. PubMed ID: 20089137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.
    Haleem DJ
    Behav Pharmacol; 2015 Feb; 26(1-2):45-58. PubMed ID: 25503261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.
    Mehler-Wex C; Riederer P; Gerlach M
    Neurotox Res; 2006 Dec; 10(3-4):167-79. PubMed ID: 17197367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
    Schülke JP; Brandon NJ
    Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postnatal neurogenesis and dopamine alterations in early psychosis.
    Inta D; Lima-Ojeda JM; Gass P; Fusar-Poli P
    Recent Pat CNS Drug Discov; 2012 Dec; 7(3):236-42. PubMed ID: 22963280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia.
    Moore H; West AR; Grace AA
    Biol Psychiatry; 1999 Jul; 46(1):40-55. PubMed ID: 10394473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal ganglia volumetric changes in psychotic spectrum disorders.
    Liu C; Cao B; Yu R; Sim K
    J Affect Disord; 2019 Aug; 255():150-157. PubMed ID: 31153051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre- and postsynaptic aspects of dopamine-mediated transmission.
    Walters JR; Ruskin DN; Allers KA; Bergstrom DA
    Trends Neurosci; 2000 Oct; 23(10 Suppl):S41-7. PubMed ID: 11052219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDE10A inhibitors: novel therapeutic drugs for schizophrenia.
    Kehler J; Nielsen J
    Curr Pharm Des; 2011; 17(2):137-50. PubMed ID: 21355834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia.
    Wang Q; Zhang W
    Front Neural Circuits; 2016; 10():105. PubMed ID: 28066191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine and the regulation of cognition and attention.
    Nieoullon A
    Prog Neurobiol; 2002 May; 67(1):53-83. PubMed ID: 12126656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease.
    Chen LW; Yung KK; Chan YS
    Curr Drug Targets; 2004 Feb; 5(2):197-206. PubMed ID: 15011953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease process and drug treatments in Parkinson's disease.
    Leenders KL
    Eur Neuropsychopharmacol; 2002 Dec; 12(6):575-80. PubMed ID: 12468020
    [No Abstract]   [Full Text] [Related]  

  • 14. Dopamine dysregulation syndrome in Parkinson's disease.
    Evans AH; Lees AJ
    Curr Opin Neurol; 2004 Aug; 17(4):393-8. PubMed ID: 15247533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synaptic and cellular plasticity in Parkinson's disease.
    Chu HY
    Acta Pharmacol Sin; 2020 Apr; 41(4):447-452. PubMed ID: 32112041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of adenosine receptors with other receptors from therapeutic perspective in Parkinson's disease.
    Morin N; Di Paolo T
    Int Rev Neurobiol; 2014; 119():151-67. PubMed ID: 25175965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia.
    Javanbakht A
    Med Hypotheses; 2006; 67(5):1173-84. PubMed ID: 16824690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural analysis of the basal ganglia in schizophrenia.
    Mamah D; Wang L; Barch D; de Erausquin GA; Gado M; Csernansky JG
    Schizophr Res; 2007 Jan; 89(1-3):59-71. PubMed ID: 17071057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schizophrenia, psychosis, and the basal ganglia.
    Busatto GF; Kerwin RW
    Psychiatr Clin North Am; 1997 Dec; 20(4):897-910. PubMed ID: 9443356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains.
    Smith Y; Villalba R
    Mov Disord; 2008; 23 Suppl 3():S534-47. PubMed ID: 18781680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.